Dosing & Uses
Dosage Forms & Strengths
ophthalmic solution (Rx)
- 0.1% (Alphagan P)
- 0.15% (Alphagan P, Qoliana)
ophthalmic solution (OTC)
- 0.025% (Lumify)
Elevated Intraocular Pressure
Indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Alphagan P, Qoliana: 1 gtt in affected eye(s) q8hr
Ocular Redness
Indicated to relieve ocular redness caused by minor eye irritations
Lumify: Instill 1 gtt in affected eye(s) q6-8hr
Optic Neuropathy (Orphan)
Treatment of anterior ischemic optic neuropathy
Orphan indication sponsor
- Allergan, Inc; 2525 Dupont Drive, P.O. Box 19534; Irvine, CA 92713
Graft vs Host Disease (Orphan)
Orphan designation for ocular GVHD
Sponsor
- Ocugen, Inc; 5 Great Valley Parkway, Suite 160; Malvern, Pennsylvania 19355
Dosage Forms & Strengths
ophthalmic solution (Rx)
- 0.1% (Alphagan P)
- 0.15% (Alphagan P, Qoliana)
ophthalmic solution (OTC)
- 0.025% (Lumify)
Elevated Intraocular Pressure
Indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
<2 years: Contraindicated
≥2 years: Alphagan P, Qoliana: 1 gtt in affected eye(s) q8hr
Ocular Redness
Indicated to relieve ocular redness caused by minor eye irritations in adults and children aged ≥5 yr
<5 years (Lumify): Safety and efficacy not established
≥5 years (Lumify): Instill 1 gtt in affected eye(s) q6-8hr
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (8)
- isocarboxazid
isocarboxazid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.
- linezolid
linezolid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.
- phenelzine
phenelzine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.
- procarbazine
procarbazine, brimonidine. Mechanism: unknown. Contraindicated.
- rasagiline
rasagiline, brimonidine. Mechanism: unknown. Contraindicated. Brimonidine should not be used in patients receiving MAO inhibitors.
- selegiline
selegiline, brimonidine. Mechanism: unknown. Contraindicated. Coadministration is contraindicated.
- selegiline transdermal
selegiline transdermal, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.
- tranylcypromine
tranylcypromine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.
Serious - Use Alternative (0)
Monitor Closely (15)
- amifostine
amifostine, brimonidine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.
- candesartan
brimonidine increases effects of candesartan by pharmacodynamic synergism. Use Caution/Monitor.
- digoxin
brimonidine increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.
- eprosartan
brimonidine increases effects of eprosartan by pharmacodynamic synergism. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, brimonidine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- irbesartan
brimonidine increases effects of irbesartan by pharmacodynamic synergism. Use Caution/Monitor.
- lasmiditan
lasmiditan, brimonidine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- losartan
brimonidine increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor.
- lurasidone
lurasidone, brimonidine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased sedation.
- nitroglycerin rectal
nitroglycerin rectal, brimonidine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .
- olmesartan
brimonidine increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor.
- sacubitril/valsartan
brimonidine increases effects of sacubitril/valsartan by pharmacodynamic synergism. Use Caution/Monitor.
- stiripentol
stiripentol, brimonidine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- telmisartan
brimonidine increases effects of telmisartan by pharmacodynamic synergism. Use Caution/Monitor.
- valsartan
brimonidine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor.
Minor (177)
- acebutolol
brimonidine increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown.
- alfentanil
brimonidine increases effects of alfentanil by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- alfuzosin
brimonidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.
- alprazolam
brimonidine increases effects of alprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- amiloride
brimonidine increases effects of amiloride by pharmacodynamic synergism. Minor/Significance Unknown.
- amitriptyline
amitriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- amlodipine
brimonidine increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown.
- amobarbital
brimonidine increases effects of amobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- amoxapine
amoxapine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- aripiprazole
brimonidine increases effects of aripiprazole by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- asenapine
brimonidine increases effects of asenapine by pharmacodynamic synergism. Minor/Significance Unknown.
- atenolol
brimonidine increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown.
- azelastine
brimonidine increases effects of azelastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- belladonna and opium
brimonidine increases effects of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- benazepril
brimonidine increases effects of benazepril by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- bendroflumethiazide
brimonidine increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown.
- benperidol
brimonidine increases effects of benperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- betaxolol
brimonidine increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown.
- bisoprolol
brimonidine increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown.
- bosentan
brimonidine increases effects of bosentan by pharmacodynamic synergism. Minor/Significance Unknown.
- brompheniramine
brimonidine increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- bumetanide
brimonidine increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown.
- buprenorphine
brimonidine increases effects of buprenorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- buprenorphine buccal
brimonidine increases effects of buprenorphine buccal by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- butabarbital
brimonidine increases effects of butabarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- butalbital
brimonidine increases effects of butalbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- butorphanol
brimonidine increases effects of butorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- captopril
brimonidine increases effects of captopril by pharmacodynamic synergism. Minor/Significance Unknown. Both drugs lower blood pressure. Monitor blood pressure.
- carbinoxamine
brimonidine increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- carvedilol
brimonidine increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown.
- celiprolol
brimonidine increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown.
- chloral hydrate
brimonidine increases effects of chloral hydrate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- chlordiazepoxide
brimonidine increases effects of chlordiazepoxide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- chlorothiazide
brimonidine increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.
- chlorpheniramine
brimonidine increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- chlorpromazine
brimonidine increases effects of chlorpromazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- chlorthalidone
brimonidine increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown.
- cinnarizine
brimonidine increases effects of cinnarizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- clemastine
brimonidine increases effects of clemastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- clevidipine
brimonidine increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown.
- clomipramine
clomipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- clonazepam
brimonidine increases effects of clonazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- clonidine
brimonidine increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown.
- clorazepate
brimonidine increases effects of clorazepate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- clozapine
brimonidine increases effects of clozapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- codeine
brimonidine increases effects of codeine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- cyclizine
brimonidine increases effects of cyclizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- cyclopenthiazide
brimonidine increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown.
- cyproheptadine
brimonidine increases effects of cyproheptadine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- desipramine
desipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- dexchlorpheniramine
brimonidine increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- dexmedetomidine
brimonidine increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- dextromoramide
brimonidine increases effects of dextromoramide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- diamorphine
brimonidine increases effects of diamorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- diazepam
brimonidine increases effects of diazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- difenoxin hcl
brimonidine increases effects of difenoxin hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- diltiazem
brimonidine increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown.
- dimenhydrinate
brimonidine increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- diphenhydramine
brimonidine increases effects of diphenhydramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- diphenoxylate hcl
brimonidine increases effects of diphenoxylate hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- dipipanone
brimonidine increases effects of dipipanone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- doxazosin
brimonidine increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown.
- doxepin
doxepin decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- doxylamine
brimonidine increases effects of doxylamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- droperidol
brimonidine increases effects of droperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- drospirenone
brimonidine increases effects of drospirenone by pharmacodynamic synergism. Minor/Significance Unknown.
- enalapril
brimonidine increases effects of enalapril by pharmacodynamic synergism. Minor/Significance Unknown.
- eplerenone
brimonidine increases effects of eplerenone by pharmacodynamic synergism. Minor/Significance Unknown.
- epoprostenol
brimonidine increases effects of epoprostenol by pharmacodynamic synergism. Minor/Significance Unknown.
- esmolol
brimonidine increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown.
- estazolam
brimonidine increases effects of estazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- ethacrynic acid
brimonidine increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown.
- ethanol
brimonidine increases effects of ethanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- etomidate
brimonidine increases effects of etomidate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- felodipine
brimonidine increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown.
- fenoldopam
brimonidine increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.
- fluphenazine
brimonidine increases effects of fluphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- flurazepam
brimonidine increases effects of flurazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- fosinopril
brimonidine increases effects of fosinopril by pharmacodynamic synergism. Minor/Significance Unknown.
- furosemide
brimonidine increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.
- guanfacine
brimonidine increases effects of guanfacine by pharmacodynamic synergism. Minor/Significance Unknown.
- haloperidol
brimonidine increases effects of haloperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- hydralazine
brimonidine increases effects of hydralazine by pharmacodynamic synergism. Minor/Significance Unknown.
- hydrochlorothiazide
brimonidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.
- hydromorphone
brimonidine increases effects of hydromorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- hydroxyzine
brimonidine increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- iloperidone
brimonidine increases effects of iloperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- iloprost
brimonidine increases effects of iloprost by pharmacodynamic synergism. Minor/Significance Unknown.
- imidapril
brimonidine increases effects of imidapril by pharmacodynamic synergism. Minor/Significance Unknown.
- imipramine
imipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- indapamide
brimonidine increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown.
- isradipine
brimonidine increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.
- ketanserin
brimonidine increases effects of ketanserin by pharmacodynamic synergism. Minor/Significance Unknown.
- labetalol
brimonidine increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.
- levorphanol
brimonidine increases effects of levorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- lisinopril
brimonidine increases effects of lisinopril by pharmacodynamic synergism. Minor/Significance Unknown.
- lofepramine
lofepramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- loprazolam
brimonidine increases effects of loprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- lorazepam
brimonidine increases effects of lorazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- lormetazepam
brimonidine increases effects of lormetazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- loxapine
brimonidine increases effects of loxapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- loxapine inhaled
brimonidine increases effects of loxapine inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- maprotiline
maprotiline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- mecamylamine
brimonidine increases effects of mecamylamine by pharmacodynamic synergism. Minor/Significance Unknown.
- meperidine
brimonidine increases effects of meperidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- meprobamate
brimonidine increases effects of meprobamate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- methadone
brimonidine increases effects of methadone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- methyclothiazide
brimonidine increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown.
- metolazone
brimonidine increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown.
- metoprolol
brimonidine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.
- metyrosine
brimonidine increases effects of metyrosine by pharmacodynamic synergism. Minor/Significance Unknown.
- midazolam
brimonidine increases effects of midazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- minoxidil
brimonidine increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.
- moexipril
brimonidine increases effects of moexipril by pharmacodynamic synergism. Minor/Significance Unknown.
- morphine
brimonidine increases effects of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- moxisylyte
brimonidine increases effects of moxisylyte by pharmacodynamic synergism. Minor/Significance Unknown.
- moxonidine
brimonidine increases effects of moxonidine by pharmacodynamic synergism. Minor/Significance Unknown.
- nadolol
brimonidine increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown.
- nalbuphine
brimonidine increases effects of nalbuphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- nebivolol
brimonidine increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown.
- nicardipine
brimonidine increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.
- nifedipine
brimonidine increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.
- nisoldipine
brimonidine increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.
- nortriptyline
nortriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- olanzapine
brimonidine increases effects of olanzapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- opium tincture
brimonidine increases effects of opium tincture by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- oxazepam
brimonidine increases effects of oxazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- oxycodone
brimonidine increases effects of oxycodone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- oxymorphone
brimonidine increases effects of oxymorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- paliperidone
brimonidine increases effects of paliperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- papaveretum
brimonidine increases effects of papaveretum by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- penbutolol
brimonidine increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown.
- pentazocine
brimonidine increases effects of pentazocine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- pentobarbital
brimonidine increases effects of pentobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- perindopril
brimonidine increases effects of perindopril by pharmacodynamic synergism. Minor/Significance Unknown.
- perphenazine
brimonidine increases effects of perphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- phenobarbital
brimonidine increases effects of phenobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- phenoxybenzamine
brimonidine increases effects of phenoxybenzamine by pharmacodynamic synergism. Minor/Significance Unknown.
- phentolamine
brimonidine increases effects of phentolamine by pharmacodynamic synergism. Minor/Significance Unknown.
- pimozide
brimonidine increases effects of pimozide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- pindolol
brimonidine increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown.
- prazosin
brimonidine increases effects of prazosin by pharmacodynamic synergism. Minor/Significance Unknown.
- primidone
brimonidine increases effects of primidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- prochlorperazine
brimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- promethazine
brimonidine increases effects of promethazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- propranolol
brimonidine increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown.
- protriptyline
protriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- quazepam
brimonidine increases effects of quazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- quetiapine
brimonidine increases effects of quetiapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- quinapril
brimonidine increases effects of quinapril by pharmacodynamic synergism. Minor/Significance Unknown.
- ramipril
brimonidine increases effects of ramipril by pharmacodynamic synergism. Minor/Significance Unknown.
- risperidone
brimonidine increases effects of risperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- secobarbital
brimonidine increases effects of secobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- silodosin
brimonidine increases effects of silodosin by pharmacodynamic synergism. Minor/Significance Unknown.
- sotalol
brimonidine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.
- spironolactone
brimonidine increases effects of spironolactone by pharmacodynamic synergism. Minor/Significance Unknown.
- sufentanil
brimonidine increases effects of sufentanil by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- tapentadol
brimonidine increases effects of tapentadol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- temazepam
brimonidine increases effects of temazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- terazosin
brimonidine increases effects of terazosin by pharmacodynamic synergism. Minor/Significance Unknown.
- thioridazine
brimonidine increases effects of thioridazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- thiothixene
brimonidine increases effects of thiothixene by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- timolol
brimonidine increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown.
- torsemide
brimonidine increases effects of torsemide by pharmacodynamic synergism. Minor/Significance Unknown.
- tramadol
brimonidine increases effects of tramadol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- trandolapril
brimonidine increases effects of trandolapril by pharmacodynamic synergism. Minor/Significance Unknown.
- trazodone
trazodone decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- treprostinil
brimonidine increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown.
- triamterene
brimonidine increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- triazolam
brimonidine increases effects of triazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- triclofos
brimonidine increases effects of triclofos by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- trifluoperazine
brimonidine increases effects of trifluoperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- trimipramine
trimipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- triprolidine
brimonidine increases effects of triprolidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- verapamil
brimonidine increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.
- ziprasidone
brimonidine increases effects of ziprasidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- zotepine
brimonidine increases effects of zotepine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
Adverse Effects
Frequency Not Defined
Oral dryness
Conjunctival hyperemia
Allergic conjunctivitis
Eye pruritus
Rash
Photophobia
Headache
Fatigue
Dizziness
Dyspepsia
Blepharitis
Eye discharge
Warnings
Contraindications
Hypersensitivity to product or components
Children <2 years (0.1-0.15% ophthalmic solution)
Cautions
Remove contact lenses before instilling eye drops; wait 15 min before reinserting contact lenses
If >1 ophthalmic product is being administered, wait 5 minutes between instilling eye drops
May potentiate syndromes associated with vascular insufficiency; caution with depression, cerebral or coronary insufficiency, Raynaud phenomenon, orthostatic hypotension, or thromboangiitis obliterans
Although brimonidine ophthalmic had minimal effect on the blood pressure of patients in clinical studies, caution with severe cardiovascular disease
Bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products; instruct patients on how to avoid contamination
Drug interaction overview
- Because brimonidine ophthalmic may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with advised
- Although specific drug interaction studies have not been conducted with brimonidine ophthalmic, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered
- Tricyclic antidepressants (TCAs) have been reported to blunt the hypotensive effect of systemic clonidine; unknown whether the concurrent use TCAs with brimonidine ophthalmic can interfere with IOP lowering effect
- MAOIs may theoretically interfere with the metabolism of brimonidine and potentially result in increased systemic effects (eg, hypotension); advise caution to patients taking MAO inhibitors
Pregnancy & Lactation
Pregnancy Category: B
Lactation: It is not known whether this drug is excreted in milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Open-Angle Glaucoma or Ocular Hypertension
- Alpha-2 adrenergic receptor agonist; decreases aqueous humor secretion, increases uveoscleral outflow
Ocular Redness
- Dilutes alpha-2 receptor agonist; rapidly eliminates redness along the bulbar conjunctival microvasculature
Pharmacokinetics
Onset of action: 2hr (peak effect)
Half-Life: 2 hr
Peak plasma time: 0.5-2.5 hr
Metabolism: Liver
Excretion: urine (74%)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Alphagan P ophthalmic (eye) - | 0.1 % drops |  | |
| Alphagan P ophthalmic (eye) - | 0.1 % drops |  | |
| Alphagan P ophthalmic (eye) - | 0.1 % drops |  | |
| Alphagan P ophthalmic (eye) - | 0.15 % drops |  | |
| Alphagan P ophthalmic (eye) - | 0.15 % drops |  | |
| Alphagan P ophthalmic (eye) - | 0.15 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.15 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.15 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.15 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| brimonidine ophthalmic (eye) - | 0.2 % drops |  | |
| Mirvaso topical - | 0.33 % gel |  | |
| Mirvaso topical - | 0.33 % gel |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
brimonidine ophthalmic (eye)
BRIMONIDINE 0.025% SOLUTION - OPHTHALMIC
(bri-MON-i-deen)
COMMON BRAND NAME(S): Lumify
USES: Brimonidine is used to relieve redness in the eyes caused by minor eye irritations (such as smog, swimming, dust, or smoke).
HOW TO USE: Read and follow all directions on the product package before using this medication. If you have any questions, consult your pharmacist. If your doctor has prescribed this medication, use it as directed.Use this medication in the affected eye(s) every 6 to 8 hours as needed. Do not use more than 4 times a day.To apply eye drops, wash hands first. To avoid contamination, do not touch the dropper tip or let it touch your eye or any other surface.If you are wearing contact lenses, remove them before using eye drops. Wait at least 10 minutes before replacing your contact lenses.Tilt your head back, look upward, and pull down the lower eyelid to make a pouch. Hold the dropper directly over your eye and place one drop into the pouch. Look downward, gently close your eyes, and place one finger at the corner of your eye (near the nose). Apply gentle pressure for 1 to 2 minutes before opening your eyes. This will prevent the medication from draining out. Try not to blink or rub your eye. Repeat these steps for your other eye if needed. Do not rinse the dropper. Replace the dropper cap after each use.If you are using another kind of eye medication (such as drops or ointments), wait at least 5 minutes before applying other medications. Use eye drops before eye ointments to allow the drops to enter the eye.Do not use if the solution has changed color or is cloudy.Tell your doctor if your condition lasts for more than 3 days or if it gets worse (such as continued eye redness/irritation, eye pain, vision changes). If you think you may have a serious medical problem, get medical help right away.
SIDE EFFECTS: If your doctor has directed you to use this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using brimonidine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history.After you apply this drug, your vision may become temporarily blurred. Do not drive, use machinery, or do any activity that needs clear vision until you can do it safely.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Keep all regular medical and lab appointments.
MISSED DOSE: Not applicable.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised July 2021. Copyright(c) 2021 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
